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Abstract
Background: The relationship of oxidative stress to thyroid hormones has not been studied in the schizophrenics.
The present study determined the status and interrelationship of plasma markers of oxidative stress, nitric oxide
and thyroid hormones in thirty (17 males and 13 females) newly diagnosed patients with acute schizophrenia
before initiation of chemotherapy. Twenty five (13 males and 12 females) mentally healthy individuals served as
controls. Patients and controls with history of hard drugs (including alcohol and cigarette), pre-diagnosis
medications (e.g. antiparkinsonian/antipsychotic drugs), chronic infections, liver disease and diabetes mellitus were
excluded from the study. Plasma levels of total antioxidant potential (TAP), total plasma peroxides (TPP), nitric oxide
(NO), malondialdehyde (MDA), thyroxine (T4), tri-iodothyronine (T3) and thyroid stimulating hormone (TSH) were
determined in all participants using spectrophotometric and enzyme linked immunosorbent assay (ELISA) methods
respectively. Oxidative stress index (OSI) was calculated as the percent ratio of total plasma peroxides and total
antioxidant potential.
Findings: Significantly higher plasma levels of MDA (p < 0.01), TPP (p < 0.01), OSI (p < 0.01), T3 (p < 0.01) and T4
(p < 0.05) were observed in schizophrenics when compared with the controls. The mean levels of TAP, NO and
TSH were significantly lower in schizophrenics (p < 0.01) when compared with the controls. The result shows that
T3 values correlate significantly with MDA (p < 0.05) and TPP (p < 0.01) in schizophrenics.
Conclusions: Higher level of TPP may enhance thyroid hormogenesis in schizophrenics. Adjuvant antioxidant
therapy may be a novel approach in the treatment of schizophrenic patients.
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Introduction
Schizophrenia is a disorder of aberrant neurodevelop-
ment with minor physical anomalies, neurological soft
signs, and abnormalities of brain structure and function
[1]. The brain abnormalities therefore cause deficits in
both working memory and long term memory tasks [2].
It is marked by disturbances in thinking, emotional
reaction, social behavior, with illusions and hallucination
[3]. Proposed factors leading to schizophrenia include
maternal exposure to stress (prenatal environmental
insults), infection and/or immune activation, nutritional
deficiencies, obstetric complications [4] and use of can-
nabis [5]. Changes in dopamine neurotransmission in
schizophrenia have been related to hallucinations and
delusions in the patients. Effective therapy which blocks
the dopamine system resolves these two clinical condi-
tions [6].
Nitric oxide (NO) is a molecule formed in the cells
through the conversion of the amino acid, L-arginine to
NO by the action of nitric oxide synthase (NOs) [7].
NO participates in other biological processes such as
vasodilatation, bronchodialation, inhibition of phagocyte,
platelets aggregation, regulation of blood pressure, and
defense against invading pathogens [8,9]. The synergistic
effects of impaired synthesis, exhaustion of NO during
anti-oxidative activities and diversion of the NO to the
peroxynitrite (ONOO) pathway could contribute to its
deregulated levels in certain disease conditions [10-12].
The vital roles played by NO in neurotransmission and
maintenance of memory make it an interesting target
molecule for schizophrenia research.
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Hydrogen peroxide, a pro-oxidant generated at physio-
logical level in the apical pole of the thyroid cells is
required by normal thyroid gland to oxidize iodide into
iodine in a reaction catalyzed by thyroperoxidase
[13-15]. Other reactions catalyzed in thyroid hormogen-
esis include the coupling of mono-iodotyrosine and di-
iodotyrosine, and in the synthesis of reverse T3 [16].
Chittiprol et al [17] reported significantly higher level of
oxidative stress and lipid peroxidation which decline
with treatment in schizophrenic patients. Yazici et al
[18] also reported significantly higher levels of thyroid
hormones in schizophrenia. None of the previous
researchers related the abnormal patterns of thyroid
hormones in schizophrenics to excessive free radical
generation. Since hydrogen peroxide catalyses a series of
chemical reactions in the synthesis of thyroid hormones,
it may be possible to have free radical induced
hyperthyroidism in schizophrenia. This study was
designed to probe further in schizophrenic research, and
bridge other gaps by determining the levels of thyroid




Thirty (17 males and 13 females) newly diagnosed
patients with acute schizophrenia (duration- between 2.5
and 4.0 months), attending Psychiatric Hospital Abeo-
kuta, Nigeria and Psychiatric Hospital Yaba, Lagos,
Nigeria were recruited for this study before initiation of
chemotherapy. The patients were traders and middle
class civil servants. Informed consent was obtained from
their relations before being included in this study. The
patients were residents of Ogun and Lagos states in
Nigeria. DSM-IV diagnosis of schizophrenia was estab-
lished by the consultant psychiatrist in charge of the
schizophrenic patients, using the Assessment of Positive
and Negative Syndrome Scale (PANSS) [19]. The schizo-
phrenic patients were either receiving spiritual treatment
or not under specific treatment before being recruited
for this study. Those patients with history of hard drugs
(including alcohol and cigarette), pre-diagnosis medica-
tions (e.g. antiparkinsonian/antipsychotic drugs), chronic
infections, liver disease and diabetes mellitus were
excluded from this study. Twenty five (13 males and 12
females) apparently healthy staff of Olabisi Onabanjo
University Teaching Hospital, Shagamu, Ogun state,
Nigeria, served as controls. None of the controls was on
any medication (including alcohol, cigarette and multivi-
tamins), had history of chronic infections, malnutrition
syndrome, depression, psychosis or metabolic dysfunc-
tion (such as diabetes mellitus, liver diseases, cancer)
that could interfere with their oxidative metabolites and
thyroid hormone status. The experimental protocol was
approved by the Research Ethical Committee of Psychia-
tric Hospital Abeokuta, Nigeria.
5 ml of venous blood sample was taken from the
anticubital vein of each participant. The sample in
lithium heparin bottle was centrifuged within one hour
of collection, after which the plasma was separated and
stored at -70°C until assayed.
Methods
T4, T3 and TSH were determined by using commer-
cially prepared enzyme linked immunosorbent assay
(ELISA) reagents (cat. numbers Z01208, Z01232 and
Z01237 respectively) by Dialab, Gesellschaft, Vienna, as
described by Young et al [20]. The MDA, a product of
lipid peroxidation was determined by using the method
of Varshney and Kale [21]. TAP was determined using
the ferric reducing/antioxidant power (FRAP) assay
[22,23]. Method of Harma et al [23] was used for the
determination of TPP. The OSI, an indicator of the
degree of oxidative stress was determined as the percent
ratio of the total plasma peroxide (μMol H2O2/L) to the
total antioxidant activity (μmol.Trolox equiv./L) [23].
NO was determined using the method described by
Wanchu et al [24].
Statistical analysis
Data processing and statistics were done using SPSS
version 10. The data were expressed as Mean ± SD. Stu-
dent (t) test was used for comparison of schizophrenics
and controls. Pearsonian correlation coefficient (r) was
calculated. The changes were considered significant,
when p-values were less than 0.05.
Findings
Age and gender distributions in the schizophrenics and
controls were expressed in Table 1. The schizophrenics
and the controls were age and sex matched. The results
of this study indicate significantly (p < 0.01) increased
plasma levels of TPP, OSI and MDA in schizophrenics
when compared with the controls. Meanwhile, the
plasma levels of NO and TAP decreased significantly (p
< 0.01) in schizophrenia when compared with the con-
trols (Table 2). This is an indication of oxidative stress
Table 1 Physical Characteristics of Schizophrenics and
Controls
Characteristics Schizophrenics (N = 30) Controls (N = 25)
Age (years) 25-43 22-45
Gender:
Male (n) 17 13
Females (n) 13 12.
N = total number of subjects used for the study
n = gender number in the study
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in the schizophrenics. The plasma levels of T3 and T4
(Table 3) increased significantly (p < 0.01 and p < 0.05
respectively) while the mean value of TSH was signifi-
cantly lower (p < 0.01) in the schizophrenic patients
when compared with the controls. There were positive
correlations observed between T3 and MDA (p <0.05)
and between T3 and TPP (p <0.01) in the schizophre-
nics (Tables 4 and 5 respectively), showing strong asso-
ciation between oxidative stress and T3 synthesis.
Discussion
Hydrogen peroxide has been identified as an important
factor in thyroid hormogenesis by the previous research-
ers. Overproduction of this pro-oxidant/free radical has
also been implicated in the pathogenesis of many dis-
ease conditions. Several reports showed that sources of
free radicals in schizophrenics include auto-oxidation of
cathecholamines, the trauma, post traumatic stress dis-
order, high neuronal activity, increased oxygen con-
sumption during high neuronal activity [25], several
chronic medical illnesses [26], somatic symptoms [27],
malnutrition, endocrine disorder and infections [4]. Oxi-
dative stress results when there is increased free radical
generation beyond the detoxification capacity of the
antioxidant defense system [28]. The possible causes of
free radical generation in our schizophrenic patients
could be malnutrition, high neuronal activity; chronic
infections and trauma (in abandoned or roughly handled
patients). Our results agree with previous researchers
[29] who reported excessive free radical generation, lipid
peroxidation and oxidative stress in schizophrenics. Evi-
dences from previous researchers also indicate increased
plasma lipid peroxidation and decreased levels of essen-
tial fatty acids in the brains of the schizophrenic patients
[30,31].
Total antioxidants potential (TAP) is an index of all
classes of antioxidants. Increased demand in the detoxi-
fication/neutralization process of free radicals or micro-
nutrient deficiency (malnutrition) may be responsible
for the lower levels of antioxidants in the schizophrenics
[28]. This increased utilization of antioxidants demon-
strated in schizophrenics leads to depressed plasma
levels and reduced urinary excretion of ascorbic acid
after an ascorbic acid load [32,33]. Our findings agree
with a number of reports which indicate significantly
lower level of total antioxidant in schizophrenics. Dad-
heech et al [28] reported significantly lower levels of
superoxide dismutase and glutathione peroxidase in
schizophrenic patients. In a study by Raffa et al [29], sig-
nificantly lower levels of superoxide dismutase and cata-
lase were also reported in schizophrenic patients. In
their study, the antioxidant deficiency was associated
with oxidative stress and malnutrition. This oxidative
stress has also been associated with the aging process
and chronic stage of the illness in some schizophrenics
investigated by Dadheech et al [28].
The ameliorative effects of antioxidant vitamins C and
E in some Wistar rats with ischemic brain injury con-
firmed the deteriorative effect of the oxidative stress in
the brain [17]. In another study, decreased plasma level
of the cell membrane antioxidant, a-tocopherol was
associated with increased oxidative stress in schizophre-
nics [34]. An increased plasma level of histamine is a
factor in the behavioral defect commonly observed in
Table 2 Markers of Oxidative Stress in Schizophrenics
and Controls
Schizophrenics Controls p values
MDA (nMol/ml) 9.5 ± 3.0 6.5 ± 1.9 < 0.01*
TPP (μMol H2O2/L) 16.5 ± 1.2 10.1 ± 0.5 < 0.01*
TAP (μMol Trolox equiv./L) 975 ± 140 1300 ± 196 < 0.01*
OSI (%) 1.7 ± 0.8 0.8 ± 0.3 < 0.01*
NO (μMol/L) 17.8 ± 6.4 24.7 ± 5.5 < 0.01*
N 30 25.
MDA = malondialdehyde. OSI = oxidative stress index
TPP total plasma peroxides. NO = nitric oxide
TAP = total antioxidant potential. N = number of subjects used in the study
* = significantly different from controls
Table 3 Thyroid Hormones Levels in Schizophrenics and
Controls
Schizophrenics Controls p -values
T3 (ng/ml) 7.5 ± 1.5 1.4 ± 0.5 < 0.01*
T4 (nmol/L) 65.0 ± 18.9 50.4 ± 12.7 < 0.05*
TSH (miU/L) 0.25 ± 0.2 1.4 ± 0.5 < 0.01*
N 30 25.
T3 = tri-iodothyronine TSH = thyroid stimulating hormone T4 = thyroxine
N = number of subjects used in the study.
* = significantly different from controls
Table 4 Correlation between MDA and thyroid hormones
in schizophrenics (N = 30)
Group Correlation coefficient (r) p-values
MDA-T3 0. 51 < 0.05*
MDA-T4 0.3 0.4
MDA-TSH 0.36 0.2.
* = significantly different from controls
N = number of subjects used in the study
Table 5 Correlation between TPP and thyroid hormones
in schizophrenics (N = 30)
Group Correlation coefficient (r) p-values
TPP-T3 0.8 < 0.01*
TPP-T4 0.46 0.15
TPP-TSH 0.41 0.09.
* = significantly different from controls
N = number of subjects used in the study
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schizophrenia [35]. In-vitro studies showed that vitamin
C reduces histamine levels by promoting the formation
of a mono-oxygenated form of N-acetylhistamine [36].
But contrary to these opinions, Straw et al [37] reported
that there was neither a change in psychopathology of
schizophrenic patients nor was there any apparent phar-
macokinetic interaction with haloperidol after ascorbic
load.
Nitric oxide is produced in the endothelia of the blood
vessels from the amino acid, L-arginine by the enzy-
matic reaction with oxygen catalyzed by nitric oxide
synthase, in the presence of NADPH, tetrahydrobiop-
terin and flavin adenine nucleotides as co-factors. The
highest concentration of NO is found in the brain for
the purpose of cell migration, formation of synapses,
receptor mediated neurotransmission, cognitive abilities
[38], maintenance of memory, and for regulation of
blood pressure [7]. Brain NO is involved in various pro-
cesses such as immunological responses, neuroplasticity,
neurodevelopment and neurotransmitter release. The
reaction between peroxides and NO in a pathway leads
to the production of peroxy-nitrite [11,12,16,39]. Per-
oxy-nitrite has greater ability to diffuse away from the
site of production and can induce more selective and
ultimately harmful oxidative damage such as the initia-
tion of lipid peroxidation [40,41]. Several research find-
ings, ranging from genetic and post mortem to
neurochemical and psychopharmacological evidence
support an involvement of the NO-signaling system in
schizophrenia pathophysiology. There have been con-
flicting reports on the levels of NO in schizophrenia:
some of them suggesting an increase of the NO-
mediated neurotransmission, and another part support-
ing a decrease [42]. Contrary to the report of Zoroglu et
al [43] who demonstrated significantly higher level of
NO and adrenomedullin in schizophrenia, our result
shows significantly lower level of NO in acute schizo-
phrenia. Diversion of the nitric oxide to the peroxy-
nitrite pathway mediated by high level of peroxides (i.e.
TPP) could cause the lower plasma level of NO in our
schizophrenic patients. Since L-arginine is the precursor
of NO, inadequate intake of L-arginine (malnutrition)
could also cause impaired synthesis and lower level of
NO in these schizophrenic patients. This finding there-
fore calls for further studies to establish the levels of
peroxy-nitrite and NO in the brain and plasma of schi-
zophrenic patients.
To the knowledge of the authors, this study is the first
to relate the plasma markers of oxidative stress with
thyroid hormogenesis in schizophrenics. In the synthesis
of thyroid hormones, hydrogen peroxide is required by
the thyroid cells to oxidize iodide into iodine in a reac-
tion catalyzed by thyroperoxidase [13-15] and also in
the coupling of mono-iodotyrosine and di-iodotyrosine,
and synthesis of reverse T3 [16]. The fact that higher
levels of total plasma peroxides and MDA correlate with
T3 in schizophrenics is the novel of this study. Our
result agrees with the reports of the previous researchers
[44] that significantly higher levels of free T3 and free
T4 are features of schizophrenia. Yazici et al [18] also
reported significantly higher levels of total T3 and free
T3 in schizophrenics when compared with the controls.
Baumgartner et al [45] also observed abnormal T4 level
in acute schizophrenic patients, but the serum level
declined in treated schizophrenic patients when com-
pared with the control.
In conclusion, oxidative stress in schizophrenics may
enhance thyroid hormone synthesis. Therefore, adjuvant
antioxidant therapy may be a novel approach in the
treatment of schizophrenic patients to avert the conse-
quences of oxidative stress.
Limitations of the study
Non-compliance of relations of many patients and lim-
ited numbers of acute cases of schizophrenia without
pre-diagnosis medications contributed to the small sam-
ple size.
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